Literature DB >> 22479046

The "con" side.

Dan Martinusen1.   

Abstract

Year:  2011        PMID： 22479046      PMCID： PMC3093424     

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  10 in total

1.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

Authors:  Tilman B Drüeke; Francesco Locatelli; Naomi Clyne; Kai-Uwe Eckardt; Iain C Macdougall; Dimitrios Tsakiris; Hans-Ulrich Burger; Armin Scherhag
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

Review 2.  American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.

Authors:  J Douglas Rizzo; Melissa Brouwers; Patricia Hurley; Jerome Seidenfeld; Murat O Arcasoy; Jerry L Spivak; Charles L Bennett; Julia Bohlius; Darren Evanchuk; Matthew J Goode; Ann A Jakubowski; David H Regan; Mark R Somerfield
Journal:  Blood       Date:  2010-10-25       Impact factor: 22.113

3.  Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

Authors:  Brian Leyland-Jones; Vladimir Semiglazov; Marek Pawlicki; Tadeusz Pienkowski; Sergei Tjulandin; George Manikhas; Antoly Makhson; Anton Roth; David Dodwell; Jose Baselga; Mikhail Biakhov; Konstantinas Valuckas; Edouard Voznyi; Xiangyang Liu; Els Vercammen
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

4.  The prevalence of anaemia in the world.

Authors:  E DeMaeyer; M Adiels-Tegman
Journal:  World Health Stat Q       Date:  1985

5.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

6.  Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Brad C Astor; Josef Coresh; Gerardo Heiss; Dan Pettitt; Mark J Sarnak
Journal:  Am Heart J       Date:  2006-02       Impact factor: 4.749

7.  Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

Authors:  James R Wright; Yee C Ung; Jim A Julian; Kathleen I Pritchard; Timothy J Whelan; Column Smith; Barbara Szechtman; Wilson Roa; Liam Mulroy; Leona Rudinskas; Bruno Gagnon; Gord S Okawara; Mark N Levine
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

8.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

9.  Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.

Authors:  Michael Henke; Roland Laszig; Christian Rübe; Ulrich Schäfer; Klaus-Dieter Haase; Burkhard Schilcher; Stephan Mose; Karl T Beer; Ulrich Burger; Chris Dougherty; Hermann Frommhold
Journal:  Lancet       Date:  2003-10-18       Impact factor: 79.321

10.  Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

Authors:  Robert E Smith; Matti S Aapro; Heinz Ludwig; Tamás Pintér; Martin Smakal; Tudor E Ciuleanu; Li Chen; Tom Lillie; John A Glaspy
Journal:  J Clin Oncol       Date:  2008-01-28       Impact factor: 44.544
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.